Characterization and trajectories of hematological parameters prior to severe COVID-19 based on a large-scale prospective health checkup cohort in western China: a longitudinal study of 13-year follow-up

BMC Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: March 7, 2024

The relaxation of the "zero-COVID" policy on Dec. 7, 2022, in China posed a major public health threat recently. Complete blood count test was discovered to have complicated relationships with COVID-19 after infection, while very few studies could track long-term monitoring status and identify characterization hematological parameters prior COVID-19.

Language: Английский

Acceptance, safety, and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in patients with primary biliary cholangitis

Heliyon, Journal Year: 2024, Volume and Issue: 10(7), P. e28405 - e28405

Published: March 19, 2024

Inactivated coronavirus disease 2019 (COVID-19) vaccines showed impaired immunogenicity in some autoimmune diseases, but it remains unclear primary biliary cholangitis (PBC). This study aimed to explore the antibody response inactivated COVID-19 vaccine individuals with PBC, as well evaluate coverage, safety, and attitudes toward among them. Two cohorts of patients PBC were enrolled this study. One cohort was arranged vaccine, another participated an online survey. The titers anti-receptor-binding domain (RBD)-specific immunoglobulin G (IgG), neutralizing (NAb) severe acute respiratory syndrome 2 wild-type, NAb Omicron BA.4/5 subvariants detected assess from vaccine. After booster vaccination for more than six months, had significantly lowered levels anti-RBD-specific IgG compared HCs, inhibition rates wild-type also declined PBC. below positive threshold HCs. Laboratory parameters did not correlate any three antibodies. survey revealed that 24% received vaccines, while 63% unimmunized. Adverse effect after first, second, third doses 6.1%, 10.3%, 9.5%, respectively. Unvaccinated worried about safety those who vaccinated (P = 0.004). As a result, fills immunological assessment gap vaccines.

Language: Английский

Safety and Efficacy of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases: A Systematic Review and Meta-Analysis

International Journal of Public Health, Journal Year: 2024, Volume and Issue: 69

Published: Nov. 21, 2024

This review aimed to assess the safety and efficacy of SARS-CoV-2 vaccines in patients with chronic liver disease (CLD).

Language: Английский